Schrödinger Past Earnings Performance
Past criteria checks 0/6
Schrödinger's earnings have been declining at an average annual rate of -20%, while the Healthcare Services industry saw earnings growing at 14% annually. Revenues have been growing at an average rate of 19.2% per year.
Key information
-20.0%
Earnings growth rate
12.4%
EPS growth rate
| Healthcare Services Industry Growth | 1.7% |
| Revenue growth rate | 19.2% |
| Return on equity | -39.5% |
| Net Margin | -91.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Schrödinger: Positive Signs Despite The Share Price Decline
Nov 21Market Participants Recognise Schrödinger, Inc.'s (NASDAQ:SDGR) Revenues Pushing Shares 26% Higher
Nov 13
Schrödinger's Path Forward: AI, Cash Burn, And Clinical Uncertainty
Oct 17Market Participants Recognise Schrödinger, Inc.'s (NASDAQ:SDGR) Revenues
Sep 27Schrodinger: More Drug Discovery Validation
Aug 06Here's Why We're Watching Schrödinger's (NASDAQ:SDGR) Cash Burn Situation
Aug 05We Think The Compensation For Schrödinger, Inc.'s (NASDAQ:SDGR) CEO Looks About Right
Jun 12Schrödinger: More Pharmaceutical Than Software
May 07Schrödinger, Inc. (NASDAQ:SDGR) Not Flying Under The Radar
May 02Schrödinger, Inc. (NASDAQ:SDGR) Analysts Just Cut Their EPS Forecasts Substantially
Mar 01Schrodinger: Conservative Guidance Sets The Stock Up For A Solid 2024
Mar 01Is Now An Opportune Moment To Examine Schrödinger, Inc. (NASDAQ:SDGR)?
Feb 28The Price Is Right For Schrödinger, Inc. (NASDAQ:SDGR) Even After Diving 26%
Feb 01Schrödinger, Inc.'s (NASDAQ:SDGR) P/S Still Appears To Be Reasonable
Dec 18Is Now An Opportune Moment To Examine Schrödinger, Inc. (NASDAQ:SDGR)?
Sep 28Is There An Opportunity With Schrödinger, Inc.'s (NASDAQ:SDGR) 49% Undervaluation?
Jul 01Schrödinger: Q2 Earnings Supports Growth Narrative
Aug 26Schrödinger appoints Dr. Geoffrey Porges as finance chief
Aug 18Sizing Up Schrodinger
Jun 06Schrödinger: Holding The Keys To Discovery
Mar 26Schrodinger: A Long-Term Hold For Biotech Investors With Upside Potential Too
Mar 15Schrödinger: Conviction Remains High, Q4 Report And Guidance Will Be Critical
Jan 06Revenue & Expenses Breakdown
How Schrödinger makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 193 | -178 | 140 | 204 |
| 30 Jun 24 | 201 | -201 | 138 | 200 |
| 31 Mar 24 | 188 | -143 | 137 | 192 |
| 31 Dec 23 | 217 | 41 | 136 | 182 |
| 30 Sep 23 | 199 | 44 | 133 | 165 |
| 30 Jun 23 | 194 | 66 | 131 | 151 |
| 31 Mar 23 | 197 | 14 | 128 | 139 |
| 31 Dec 22 | 181 | -149 | 121 | 126 |
| 30 Sep 22 | 170 | -153 | 112 | 117 |
| 30 Jun 22 | 163 | -148 | 105 | 107 |
| 31 Mar 22 | 154 | -135 | 96 | 97 |
| 31 Dec 21 | 138 | -100 | 86 | 91 |
| 30 Sep 21 | 125 | -81 | 81 | 83 |
| 30 Jun 21 | 121 | -42 | 72 | 77 |
| 31 Mar 21 | 114 | -11 | 65 | 72 |
| 31 Dec 20 | 108 | -24 | 60 | 65 |
| 30 Sep 20 | 101 | -20 | 54 | 58 |
| 30 Jun 20 | 95 | -35 | 52 | 52 |
| 31 Mar 20 | 91 | -33 | 52 | 45 |
| 31 Dec 19 | 86 | -25 | 48 | 39 |
| 30 Sep 19 | 77 | -24 | 46 | 37 |
| 30 Jun 19 | 70 | -24 | 43 | 36 |
| 31 Mar 19 | 69 | -29 | 38 | 35 |
| 31 Dec 18 | 67 | -28 | 36 | 35 |
| 31 Dec 17 | 56 | -17 | 31 | 28 |
Quality Earnings: SDGR is currently unprofitable.
Growing Profit Margin: SDGR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SDGR is unprofitable, and losses have increased over the past 5 years at a rate of 20% per year.
Accelerating Growth: Unable to compare SDGR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SDGR is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (13.9%).
Return on Equity
High ROE: SDGR has a negative Return on Equity (-39.51%), as it is currently unprofitable.